Switch of tablet manufacturing from high shear granulation to twin-screw granulation using quality by design approach.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
15 Apr 2020
Historique:
received: 30 10 2019
revised: 10 02 2020
accepted: 11 02 2020
pubmed: 18 2 2020
medline: 29 12 2020
entrez: 17 2 2020
Statut: ppublish

Résumé

This study aimed to transfer a high shear granulation (HSG) process to a twin-screw granulation (TSG) process while maintaining equivalent dissolution profiles. Ibuprofen (IBP) was used as poorly soluble model drug. Granules were obtained by HSG or TSG according to a full factorial design. The liquid-to-solid ratio and wet massing time (HSG) or powder throughput (TSG) were selected as factors. The granules were compressed to tablets with immediate release and a drug load of 50% (w/w). Quality attributes (QAs) of the granules, especially the granule strength (GS), and the resulting tablets were evaluated. The effect of process parameters on the QAs was statistically analyzed. The comparison of HSG tablets with TSG tablets revealed that TSG tablets showed higher tensile strength and lower ejection force than HSG tablets. The dissolution profiles of the tablets in different pH media were also evaluated. Equivalent dissolution profiles in all four media (e.g., f

Identifiants

pubmed: 32061724
pii: S0378-5173(20)30123-X
doi: 10.1016/j.ijpharm.2020.119139
pii:
doi:

Substances chimiques

Excipients 0
Powders 0
Tablets 0
Ibuprofen WK2XYI10QM

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119139

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yuta Miyazaki (Y)

Heinrich Heine University, Institute of Pharmaceutics and Biopharmaceutics, Universitaetsstr. 1, 40225 Duesseldorf, Germany; ONO Pharmaceutical Co., Ltd., CMC & Production HQs, Pharmaceutical Product Development & Management, Pharmaceutical Product Development, Non-Sterile Product, 15-26 Kamiji 1-Chome Higashinari-ku, 537-0003 Osaka, Japan.

Vincent Lenhart (V)

Heinrich Heine University, Institute of Pharmaceutics and Biopharmaceutics, Universitaetsstr. 1, 40225 Duesseldorf, Germany.

Peter Kleinebudde (P)

Heinrich Heine University, Institute of Pharmaceutics and Biopharmaceutics, Universitaetsstr. 1, 40225 Duesseldorf, Germany. Electronic address: kleinebudde@hhu.de.

Articles similaires

Aspergillus Hydrogen-Ion Concentration Coculture Techniques Secondary Metabolism Streptomyces rimosus
Animals Dietary Fiber Dextran Sulfate Mice Disease Models, Animal
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Classifications MeSH